what is a glp-1 agonist medication FORMULATION DEVELOPMENT Lower doses of the GLP-1

Female sexual desire disorder (clinical) PT-141 FDA-approved for HSDD in premenopausal women with defined efficacy from Phase 3 pivotal trials Melanocortin receptor pharmacology research Melanotan-2 Non-selective agonist profile allows study of MC1R through MC5R activation and multi-system melanocortin signaling Sexual function with regulatory backing PT-141 Only melanocortin-based sexual function treatment with FDA approval and standardized prescription dosing Melanogenesis and tanning research Melanotan-2 Higher MC1R agonist activity produces more robust melanogenesis than PT-141, which was optimized away from tanning effects Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly

Rare side effects Allergic reaction: Signs include hives, swelling, difficulty breathing, or chest tightness

Unlike other treatments for sexual dysfunction, PT-141 acts on the central nervous system, making it effective for both men and women in increasing libido and improving sexual satisfaction

Bhattacharya S

This coordinated engagement across the pancreas, brain, gut, liver, and adipose tissue underlies the mechanistic rationale for dual GLP-1/GIP receptor agonists, and explains why they have been described as super GLP-1RAs, reflecting genuine potentiation of GLP-1 action by GIP receptor agonist co-activation

For systemic or musculoskeletal use, subcutaneous injection is the standard route